BACKGROUND: The U.S. Office for Human Research Protections has proposed that end points of randomized trials comparing the effectiveness of standard medical practices are risks of research that would require disclosure and written informed consent, but data are lacking on the views of potential participants. OBJECTIVE: To assess attitudes of U.S. adults about risks and preferences for notification and consent for research on medical practices. DESIGN: Cross-sectional survey conducted in August 2014. SETTING: Web-based questionnaire. PATIENTS: 1095 U.S. adults sampled from an online panel (n = 805) and an online convenience river sample (n = 290). MEASUREMENTS: Attitudes toward risk, informed consent, and willingness to participate in 3 research scenarios involving medical record review and randomization of usual medical practices. RESULTS: 97% of respondents agreed that health systems should evaluate standard treatments. Most wanted to be asked for permission to participate in each of 3 scenarios (range, 75.2% to 80.4%), even if it involved only medical record review, but most would accept nonwritten (oral) permission or general notification if obtaining written permission would make the research too difficult to conduct (range, 70.2% to 82.7%). Most perceived additional risk from each scenario (range, 64.0% to 81.6%). LIMITATION: Use of hypothetical scenarios and a nonprobability sample that was not fully representative of the U.S. population. CONCLUSION: Most respondents preferred to be asked for permission to participate in observational and randomized research evaluating usual medical practices, but they are willing to accept less elaborate approaches than written consent if research would otherwise be impracticable. These attitudes are not aligned with proposed regulatory guidance. PRIMARY FUNDING SOURCE: National Center for Advancing Translational Sciences at the National Institutes of Health.
BACKGROUND: The U.S. Office for Human Research Protections has proposed that end points of randomized trials comparing the effectiveness of standard medical practices are risks of research that would require disclosure and written informed consent, but data are lacking on the views of potential participants. OBJECTIVE: To assess attitudes of U.S. adults about risks and preferences for notification and consent for research on medical practices. DESIGN: Cross-sectional survey conducted in August 2014. SETTING: Web-based questionnaire. PATIENTS: 1095 U.S. adults sampled from an online panel (n = 805) and an online convenience river sample (n = 290). MEASUREMENTS: Attitudes toward risk, informed consent, and willingness to participate in 3 research scenarios involving medical record review and randomization of usual medical practices. RESULTS: 97% of respondents agreed that health systems should evaluate standard treatments. Most wanted to be asked for permission to participate in each of 3 scenarios (range, 75.2% to 80.4%), even if it involved only medical record review, but most would accept nonwritten (oral) permission or general notification if obtaining written permission would make the research too difficult to conduct (range, 70.2% to 82.7%). Most perceived additional risk from each scenario (range, 64.0% to 81.6%). LIMITATION: Use of hypothetical scenarios and a nonprobability sample that was not fully representative of the U.S. population. CONCLUSION: Most respondents preferred to be asked for permission to participate in observational and randomized research evaluating usual medical practices, but they are willing to accept less elaborate approaches than written consent if research would otherwise be impracticable. These attitudes are not aligned with proposed regulatory guidance. PRIMARY FUNDING SOURCE: National Center for Advancing Translational Sciences at the National Institutes of Health.
Authors: Kathleen M Mazor; James E Sabin; Sarah L Goff; David H Smith; Sharon Rolnick; Douglas Roblin; Marsha A Raebel; Lisa J Herrinton; Jerry H Gurwitz; Denise Boudreau; Vanessa Meterko; Katherine S Dodd; Richard Platt Journal: Pharmacoepidemiol Drug Saf Date: 2009-07 Impact factor: 2.890
Authors: Benjamin S Wilfond; David Magnus; Armand H Antommaria; Paul Appelbaum; Judy Aschner; Keith J Barrington; Tom Beauchamp; Renee D Boss; Wylie Burke; Arthur L Caplan; Alexander M Capron; Mildred Cho; Ellen Wright Clayton; F Sessions Cole; Brian A Darlow; Douglas Diekema; Ruth R Faden; Chris Feudtner; Joseph J Fins; Norman C Fost; Joel Frader; D Micah Hester; Annie Janvier; Steven Joffe; Jeffrey Kahn; Nancy E Kass; Eric Kodish; John D Lantos; Laurence McCullough; Ross McKinney; William Meadow; P Pearl O'Rourke; Kathleen E Powderly; DeWayne M Pursley; Lainie Friedman Ross; Sadath Sayeed; Richard R Sharp; Jeremy Sugarman; William O Tarnow-Mordi; Holly Taylor; Tom Tomlinson; Robert D Truog; Yoram T Unguru; Kathryn L Weise; David Woodrum; Stuart Youngner Journal: N Engl J Med Date: 2013-06-05 Impact factor: 91.245
Authors: Ruth Macklin; Lois Shepherd; Alice Dreger; Adrienne Asch; Francoise Baylis; Howard Brody; Larry R Churchill; Carl H Coleman; Ethan Cowan; Janet Dolgin; Jocelyn Downie; Rebecca Dresser; Carl Elliott; M Carmela Epright; Ellen K Feder; Leonard H Glantz; Michael A Grodin; William Hoffman; Barry Hoffmaster; David Hunter; Ana S Iltis; Jonathan D Kahn; Nancy M P King; Rory Kraft; Rebecca Kukla; Lewis Leavitt; Susan E Lederer; Trudo Lemmens; Hilde Lindemann; Mary Faith Marshall; Jon F Merz; Frances H Miller; Margaret E Mohrmann; Haavi Morreim; Meryl Nass; James L Nelson; John H Noble; Elizabeth Reis; Susan M Reverby; Anita Silvers; Aron C Sousa; Roy G Spece; Carson Strong; Judith P Swazey; Leigh Turner Journal: N Engl J Med Date: 2013-06-26 Impact factor: 91.245
Authors: Waldemar A Carlo; Neil N Finer; Michele C Walsh; Wade Rich; Marie G Gantz; Abbot R Laptook; Bradley A Yoder; Roger G Faix; Abhik Das; W Kenneth Poole; Kurt Schibler; Nancy S Newman; Namasivayam Ambalavanan; Ivan D Frantz; Anthony J Piazza; Pablo J Sánchez; Brenda H Morris; Nirupama Laroia; Dale L Phelps; Brenda B Poindexter; C Michael Cotten; Krisa P Van Meurs; Shahnaz Duara; Vivek Narendran; Beena G Sood; T Michael O'Shea; Edward F Bell; Richard A Ehrenkranz; Kristi L Watterberg; Rosemary D Higgins Journal: N Engl J Med Date: 2010-05-16 Impact factor: 91.245
Authors: Rachel Topazian; Juli Bollinger; Kevin P Weinfurt; Rachel Dvoskin; Debra Mathews; Kathleen Brelsford; Matthew DeCamp; Jeremy Sugarman Journal: J Comp Eff Res Date: 2016-07-15 Impact factor: 1.744
Authors: Stephanie A Kraft; Melissa Constantine; David Magnus; Kathryn M Porter; Sandra Soo-Jin Lee; Michael Green; Nancy E Kass; Benjamin S Wilfond; Mildred K Cho Journal: Clin Trials Date: 2016-09-23 Impact factor: 2.486
Authors: Neal W Dickert; David Wendler; Chandan M Devireddy; Sara F Goldkind; Yi-An Ko; Candace D Speight; Scott Yh Kim Journal: Clin Trials Date: 2018-10-03 Impact factor: 2.486